Golidocitinib NEW
| Price | $98 | $147 | $259 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-17 |
Product Details
| Product Name: Golidocitinib | CAS No.: 2091134-68-6 |
| Purity: 99.88% | Supply Ability: 10g |
| Release date: 2026/07/17 |
Product Introduction
Bioactivity
| Name | Golidocitinib |
| Description | Golidocitinib (AZD4205) is a selective JAK1 inhibitor with an IC50 of 73 nM, while it weakly inhibits JAK2 and JAK3 with IC50 values greater than 14.7 μM and 30 μM, respectively. |
| In vitro | AZD4205 significantly inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50: 161 nM). |
| In vivo | AZD4205, administered orally at doses of 12.5 mg/kg, 25 mg/kg, or 50 mg/kg twice daily (BID), exhibits dose-dependent antitumor effects when used alone. Additionally, it boosts the antitumor efficacy of osimertinib when compared to the administration of osimertinib alone in mice implanted with NCI-H1975 cells. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 145 mg/mL (296.18 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.21 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (20.43 mM), Solution. |
| Keywords | Janus kinase | JAK1 | JAK | Inhibitor | inhibit | Golidocitinib | AZD-4205 | AZD 4205 |
| Inhibitors Related | Delgocitinib | Ruxolitinib | Atinvicitinib | Tofacitinib Citrate | Resveratrol | 2-(1,8-naphthyridin-2-yl)phenol | Filgotinib | JAK-IN-10 | Tofacitinib | 2,4,5-Trimethoxybenzoic acid | Lentinan | Raspberry ketone glucoside |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $98.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY